Hoffmann-La Roche Inc. could find itself paying up to $90 million or more for a preclinical research program with transplant rejection and rheumatoid arthritis applications. (BioWorld Today)
Hoffmann-La Roche Inc. could find itself paying up to $90 million or more for a preclinical research program with transplant rejection and rheumatoid arthritis applications. (BioWorld Today)
Praecis Pharmaceuticals Inc. continues to expect regulatory approval for Plenaxis despite an FDA decision to delay action on the new drug application by three months. (BioWorld Today)
Praecis Pharmaceuticals Inc. continues to expect regulatory approval for Plenaxis despite an FDA decision to delay action on the new drug application by three months. (BioWorld Today)
